EFFICACY OF IMMUNOMODULATORS AND ANTIOXIDANTS IN THE CORRECTION OF IMPAIRED IMMUNE STATUS PARAMETERS IN PATIENTS WITH ADENOMYOSIS

The aim of the study was to study the effectiveness of the use of immunomodulators and antioxidants in the correction of immune status parameters in patients with adenomyosis. 70 patients were examined, including 57 women (the main group), who were diagnosed with adenomyosis according to the results of a comprehensive clinical, ultrasound and hysteroscopic examination. The control group consisted of 23 gynecologically healthy women. After verification of the diagnosis, all patients with hypertension received standard treatment (SL) (clinical recommendations of the Ministry of Health of the Russian Federation from 2016). Among the female patients, 19 women received only SL (1^st subgroup). 38 exhaust gases examined, in addition to SL, received various combinations of antioxidant, immunomodulator, and membrane protector and were divided into two subgroups. The second subgroup included 20 patients in addition to the SL receiving sodium ribonucleate; Hypoxene and phospholipids. The third subgroup included 18 patients who additionally received Inosine + Nicotinamide + Riboflavin + Succinic acid; Meglumine acridone acetate, and glycyrrhizic acid + phospholipids. The analysis of the cytokine status and the compliment system was performed at the time of admission and by the 15^th day of observation. Detected changes of the cytokine status, complement system activation, increased oxygen-dependent activity of neutrophils in the peripheral blood (increased production of active oxygen forms as a result of respiratory burst) confirm the presence of immune inflammation on the systemic level. Insufficient clinical-laboratory efficacy of ST in the correction of immune changes has justified the use of drugs with immunomodulating, antioxidant, and membrane protective properties in the pharmacological therapy of adenomyosis, which have been successfully used in the treatment of other diseases with similar disorders.Optimal combinations of immunomodulators and antioxidants in the correction of the immune status of patients with adenomyosis were revealed. The study performed demonstrates the efficacy of correcting immune status parameters in patients with adenomyosis when the standard treatment is combined with antioxidant and immunomodulating agents. 

1. Adamyan L.V., Kulakov V.I., Andreeva E.N. Endometriosis. Clinical guidelines. Moscow, 2016.

2. Chuchalin A.G., Yasnetsov V.V. Federal guidelines for the use of drugs (formulary system). Moscow, 2014- 2016, pp. 15-17.

3. Dzhamalutdinova K.M., Kozachenko I.F., Gus A.I., Adamyan L.V. Modern aspects of the pathogenesis and diagnosis of adenomyosis. Оbstetrics and Gynecology, 2018, no. 1, pp. 29-34. (In Russ.)

4. Feldman N., Rotter-Maskowitz A., Okun E. DAMPs as mediators of sterile inflammation in aging-related pathologies. Ageing Res. Rev., 2015, Vol. 24 (Pt A), pp. 29-39.

5. Harada T., Khine Y.M., Kaponis A., Nikellis T., Decavalas G., Taniguchi F. The impact of adenomyosis on women’s fertility. Obstet. Gynecol. Surv., 2016, Vol. 71, no. 9, pp. 557-568.

6. Invitti A. L., Schor E., Parreira R.M., Kopelman A., Kamergorodsky G., Gonçalves G.A., Batista Castello Girão M.J. Inflammatory cytokine profile of co cultivated primary cells from the endometrium of women with and without endometriosis. Mol. Med. Rep., 2018, Vol. 18, no. 2, pp. 1287-1296.

7. Konoplya A.A., Ivanova O.Yu., Bystrova N.A., Telegina O.V. Clinical and laboratory effectiveness of standards of care in internal endometriosis. Kursk Scientific and Practical Bulletin “Man and his Health”, 2018, no. 1, рр. 10-16.

8. Ovakimyan A.S., Krechetova L.V., Vtorushina V.V., Van’ko L.V., Kozachenko I.F., Adamyan L.V. The content of interleukin-1β, interleukin-8 and substance P in the blood plasma and peritoneal fluid of patients with various forms of external genital endometriosis and chronic pelvic pain. Оbstetrics and Gynecology, 2015, no. 3, рр. 79-86. (In Russ.)

9. Sosnin A.N., Kalinina N.M., Berlev I.V. The content of pro- and anti-inflammatory cytokines, platelet growth factor in peritoneal fluid in women with external genital endometriosis. Cytokines and Inflammation, 2013, Vol. 12, no. 4, рр. 92-95. (In Russ.)

10. Spits H., Artis D., Colonna M., Diefenbach A., DiSanto J.P., Eberl G., Koyasu S., Locksley R.M., McKenzie A.N., Mebius R.E., Powrie F., Vivier E. Innate lymphoid cells – aproposal for a uniform nomenclature. Nat. Rev. Immunol., 2013, Vol. 13, pp. 145-149.

11. Yarilin D.A. The role of tumor necrosis factor in the regulation of the inflammatory response of monocytes and macrophages. Immunologiya, 2014, no. 4, рр. 195-200. (In Russ.)

12. Zaporozhan V.M., Evdokimova V.V. Combined therapy of external genital endometriosis by immunomodulators. Reproductive Endocrinology, 2012, Vol. 6, no. 8. (In Russ.)

13. Zemskov A.M., Zemskov V.M., Esaulenko I.E., Zemskov M.A., Tonkikh R.V., Zoloedov V.I. New principles for the assessment and correction of immunological disorders. Moscow: Triada-Х, 2008. 336 р.